QDx Pathology Services
QDx Pathology Services is a US national clinical and anatomical pathology laboratory providing diagnostic testing services to physicians, clinics, and medical institutions. Founded in 2006, it now operates under the LabGenomics brand following a 2026 consolidation.
- Company typePrivate
- Founded2006
- HeadquartersCranford, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What QDx Pathology Services does
QDx Pathology Services is a national, independent, full-service clinical and anatomical pathology laboratory founded in 2006 and headquartered in Cranford, New Jersey. The company provides pathology and molecular diagnostic testing services to physicians, clinics, and medical institutions across the United States, addressing the need for comprehensive diagnostic capabilities delivered with continuous service quality.
The company's core offering combines clinical and anatomical pathology with molecular diagnostics, operating a single comprehensive diagnostic platform. It also facilitates overseas referral testing services for specialized diagnostics, including blood-based Alzheimer's disease testing, enabling access to advanced testing capabilities that may not be domestically available. The customer base is segmented horizontally across healthcare providers, with no vertical specialization disclosed.
QDx Pathology Services operated as a private subsidiary of LabGenomics, a national diagnostics company. In May 2026, parent LabGenomics consolidated QDx Pathology Services and Integrated Molecular Diagnostics (IMD) under the unified LabGenomics brand, merging previously separate pathology and molecular testing entities into a single identity while maintaining the same operational teams and service portfolio. The company's website (qdxpath.com) now redirects to labgusa.com. In parallel, QDx established a partnership with Daewoong Bio to provide overseas referral testing services to Korean medical institutions. CEO M. Nasar Qureshi leads the organization, which employs 101-250 people. No pricing, revenue, funding, or investor information has been publicly disclosed.
QDx Pathology Services firmographics
Firmographics- Name
- QDx Pathology Services
- Legal name
- QDx Pathology Services
- Website
- https://qdxpath.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- QDx Pathology Services is a US national clinical and anatomical pathology laboratory providing diagnostic testing services to physicians, clinics, and medical institutions. Founded in 2006, it now operates under the LabGenomics brand following a 2026 consolidation.
- Ownership category
- akta.pro rank
QDx Pathology Services industry classification
Industry- Product category
- Clinical Pathology Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where QDx Pathology Services is headquartered
LocationHeadquarters
- HQ city
- Cranford
- HQ country
- United States
- HQ region
- North America
Markets served
QDx Pathology Services business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
QDx Pathology Services product offering
Product offeringCore offering
QDx Pathology Services was a national, independent, full-service clinical and anatomical pathology laboratory that provided pathology and molecular diagnostic testing to physicians, clinics, and medical institutions in the United States. As of May 2026, it was unified with Integrated Molecular Diagnostics under the LabGenomics brand to deliver a consolidated pathology and molecular diagnostic platform while maintaining uninterrupted service quality.
Product overview
QDx Pathology Services operated as a national diagnostics company offering pathology and molecular testing services. As of May 2026, QDx Pathology Services and its subsidiary Integrated Molecular Diagnostics have been unified under the LabGenomics brand, consolidating pathology and molecular testing capabilities into a single, more comprehensive diagnostic platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Pathology Services Full-service clinical pathology laboratory testing services delivered to physicians, clinics, and medical institutions in the United States.
- Anatomical Pathology Services Full-service anatomical pathology testing services delivered to healthcare providers as part of the laboratory's diagnostic offering.
- Molecular Diagnostic Testing Molecular diagnostics testing provided through the QDx Pathology platform and unified under the LabGenomics brand alongside Integrated Molecular Diagnostics.
- Overseas Referral Testing Services US-based specialized diagnostic testing services offered to Korean medical institutions via the partnership with Daewoong Bio and LabGenomics, including advanced diagnostics such as blood-based Alzheimer's disease testing.
Companies that use QDx Pathology Services
Customer profileSegments1 record
Ideal customer profiles1 record
QDx Pathology Services technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
QDx Pathology Services partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Daewoong BiocoreQDx Pathology Services, as a US-based company, partners with Daewoong Bio and LabGenomics to provide overseas referral testing services. This partnership enables domestic Korean medical institutions to access specialized diagnostic testing capabilities through QDx Pathology's US-based laboratory services, particularly for advanced diagnostics requiring international testing facilities.
- LabGenomicscoreQDx Pathology Services is a subsidiary of LabGenomics, a national diagnostics company. In May 2026, QDx Pathology Services and Integrated Molecular Diagnostics transitioned to the LabGenomics brand, unifying pathology and molecular testing capabilities under a single identity. The consolidation maintains uninterrupted service quality for healthcare providers.
Recent moves4 records
Expansion highlights3 records
QDx Pathology Services competitors and assessment
Company assessmentBroad incumbents
- Sonic Healthcare USA: International diagnostics network with significant US pathology operations. Comparable as a multi-region clinical/anatomical pathology provider competing for physician and clinic accounts, with analogous mix of routine and specialty testing.
- Quest Diagnostics: Largest US independent clinical and anatomical pathology laboratory network. Directly comparable to QDx Pathology Services in test menu and provider customer base, but operates at vastly greater national scale and serves as the primary incumbent QDx competes against.
- Laboratory Corporation of America (Labcorp): Major US national clinical and anatomical pathology lab with broad molecular and esoteric testing capabilities. Closely comparable service mix to QDx Pathology Services but with substantially larger scale, hospital/health-system contracts, and assay development resources.
Emerging players
- Natera: Molecular diagnostics company with cell-free DNA and specialty genetic testing. Comparable as a molecular diagnostics provider competing for physician-ordered specialty tests, but more focused on reproductive oncology and transplant rather than broad pathology.
- NeoGenomics: US specialty oncology-focused clinical and molecular pathology laboratory. Comparable in molecular and anatomical pathology delivery to providers, though more narrowly focused on oncology than QDx's broader full-service positioning.
- Guardant Health: US-based molecular diagnostics company specializing in liquid biopsy and oncology genomics. Comparable to QDx in offering molecular diagnostic testing to clinicians, but focused on a narrower oncology niche and competing for the molecular portion of QDx's menu.
Direct peers
- ARUP Laboratories: National reference laboratory affiliated with the University of Utah, offering comprehensive clinical, anatomical, and molecular pathology testing. Comparable as a non-national-incumbent full-service pathology lab competing for hospital and specialty testing contracts.
- BioReference Health (OPKO Health): US-based full-service clinical and molecular diagnostics laboratory serving physicians, clinics, and health systems. Directly comparable in offering mix (anatomical pathology plus molecular), customer base (community providers), and scale tier relative to QDx Pathology Services.
Regional players
- Mayo Clinic Laboratories: Hospital-affiliated national reference laboratory offering esoteric and routine clinical/anatomical pathology. Comparable as a full-service pathology reference lab competing for specialty send-out testing from US providers.
Others
- LabGenomics: Korean national diagnostics company and parent of QDx Pathology Services. Directly comparable as a clinical and molecular pathology provider, and the corporate parent under which QDx has now been rebranded and consolidated.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
QDx Pathology Services financial estimates
Financial estimateRevenue estimate
Valuation estimate
QDx Pathology Services leadership team
Management profileNumber of profiles
Profiles1 record
QDx Pathology Services funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QDx Pathology Services M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QDx Pathology Services
What does QDx Pathology Services do?
QDx Pathology Services was a national, independent, full-service clinical and anatomical pathology laboratory that provided pathology and molecular diagnostic testing to physicians, clinics, and medical institutions in the United States. As of May 2026, it was unified with Integrated Molecular Diagnostics under the LabGenomics brand to deliver a consolidated pathology and molecular diagnostic platform while maintaining uninterrupted service quality.
Is QDx Pathology Services a public or private company?
QDx Pathology Services is a private company. It is classified as corporate owned and is currently acquired.
When was QDx Pathology Services founded?
QDx Pathology Services was founded in 2006. It employs 101 to 250 people.
Where is QDx Pathology Services based?
QDx Pathology Services is headquartered in Cranford, United States, in the North America region.
Who are QDx Pathology Services's main competitors?
Broad incumbents on record are Sonic Healthcare USA, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Emerging players are Natera, NeoGenomics and Guardant Health. Direct peers are ARUP Laboratories and BioReference Health (OPKO Health). Mayo Clinic Laboratories is listed as a regional player. LabGenomics is listed as an others.
Does QDx Pathology Services have an API?
No public API is recorded for QDx Pathology Services.
What industry is QDx Pathology Services in?
QDx Pathology Services's product category is Clinical Pathology Laboratory Services. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.